Breakthrough T1D

Breakthrough T1D, formerly known as JDRF (Juvenile Diabetes Research Foundation), is a leading global nonprofit organization dedicated to type 1 diabetes (T1D) research and advocacy. Founded in 1970 by parents of children with T1D, its mission is to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. The organization's headquarters are located in New York, New York, US.

Breakthrough T1D primarily funds and drives research aimed at restoring the body's ability to produce insulin, preventing T1D onset, and providing insulin independence, while also working to improve the daily lives of those affected. The organization supports the development of new therapies and treatments, including advancements in Artificial Pancreas (AP) Systems, Continuous Glucose Monitors (CGM), and drugs like Tzield. Beyond research, it engages in significant advocacy efforts, championing federal funding for T1D research through programs like the Special Diabetes Program, influencing policy, and working to ensure access to affordable insulin and critical medical advancements.

In June 2024, the organization rebranded from JDRF to Breakthrough T1D to better reflect its focus on individuals of all ages living with T1D and its leadership in accelerating scientific discovery and therapeutic development. Aaron J. Kowalski, Ph.D., who lives with T1D himself, serves as the Chief Executive Officer. The organization continues to be a major force in the T1D community, having invested over $2.1 billion in diabetes research since its inception and recently announcing new International Board of Directors leadership with Karen Shishino Jordan as Chair and Carlton McMillan as Vice Chair, effective July 1, 2026.